ClinicalTrials.gg
RecruitingNCT06363396Updated Apr 12, 2024

Fatigue and Cognitive Dysfunction After Allogeneic Stemcell Transplantation, Prospective PET Study

An observational study in Fatigue and Cognitive Dysfunction, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-12.

Sponsored by Karolinska Institutet · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Fatigue with a site in Sweden — 14 open to participants now, 15 under way, none of them phase 3. Fatigue · Sweden.

Planned enrollment
13th of 15
30 · median 100
Started
2024
with 3 others
Observational
15 of 43
5 open now
Primary completion
2026-02
later than 5 of 14 live
Registered
32nd of 43
by date
Lead sponsor
9 of 43
Karolinska Institutet

Among the 43 studies in Fatigue with a site in Sweden, this one is the 13th largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2024, is one of 15 observational ones, reaches primary completion later than 5 of the 14 other live ones, and was the 32nd registered.

Fatigue

2,234 studies on the registry are indexed under Fatigue; 430 are open to participants now.

Browse Fatigue studies →

Open to participants now

14 of the 43 studies in Fatigue with a site in Sweden are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 242 Fatigue studies recruiting now, 113 (47%) set no upper age limit and 99 (41%) stop at 75 or younger; 23 take children under 18; 74 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Fatigue with a site in Sweden, or all of them as a file.
02

Study summary

This study is the academic study and continuation and further development of a prior project under the leadership of Professor LeBlanc. Patients undergoing allogenic stem cell transplantation are followed up in the outpatient clinic. Here, patients are offered participation the fatigue study measuring both fatigue and cognitive impairment systematically by international standard. Previous study by Boberg et al suggested distinct mRNA and proteomic profiles segregating fatigued from non-fatigued patients as well as patients with or without cognitive impairment. A larger well-defined patient cohort is necessary to confirm these results. Investigators aim to identify specific sets of proteins in the CSF that can serve as potential biomarkers of cognitive dysfunction and/or fatigue. This will be performed with two methods:

  • by using mass spectrometry-based proteomics approaches
  • Olink technology

PET examinations will be performed on both fatigued and non-fatigued. We will utilize the second generation TSPO radioligand [ 11C]PBR28 as well as the SV2A radioligand [ 11C]UCB-J, both showing high signal-to-noise ratio and adequate test-retest properties.

Read the detailed description

Investigators plan to enroll 30 patients. Blood and liquor samples will be processed, frozen and stored in biobanks. In addition to the clinical tests we will analyze a large set of proinflammatory cytokines and performed and advanced immunophenotyping to determine the exact signature of immune cells in the blood and and in the liquor. The clinical data after will be systematically analyzed in an uni- and multivariate fashion for underlying risk factors, medications and outcome. This unique set of high quality clinical data together with the results from the lab and the radioimaging will provide a unique data set allowing to answer the research questions associated with the underlying hypothesis.Investigators plan to validate previous findings in a larger cohort and test whether neurocognitive testing battery can predict who will develop fatigue and cognitive dysfunction (CD). We evaluate patients using the Mental Fatigue Scale, Fatigue Severity Scale, and Cambridge Neuropsychological Test Automated Battery (CANTAB) as previously described by our group. Investigators will implement other test batteries (such as GERAS) and evaluate relevance for transplanted patients. Study aims to obtain novel insights into the pathophysiology of fatigue and CD, enabling accurate diagnosis and quantification of the severity. Findings may also be important for other long-term survivors after cancer. The study is expected to generate knowledge on the interaction between immune and synaptic functions which is relevant both for CNS disorders such as MS and Alzheimer's disease but also hematologic malignancies. It ensures the safety of individuals undergoing therapy while successful resolution of complications contributes to the long-term efficacy, promoting sustained health improvement. CANTAB might be directly implemented in the clinic as a tool to evaluate the need for sick-leave and the ability to return to work. Advanced imaging techniques will hopefully become a part of clinical praxis, facilitating the development of targeted interventions.

All patients will perform blood sampling, lumbal puncture, cognitive tests and neuroimaging with PET and MRI.

03

Conditions studied

  • Fatigue
  • Cognitive Dysfunction
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 20-75, both male and female who are 1-5 years after allogeneic stem cell transplantation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • status 1-5 years after
  • no known CNS disorders or psychiatric disturbances

Exclusion criteria

Exclusion Criteria:

  • prior TBI or CNS irradiation / intrathecal therapy
  • known neurological or psychiatric disorder
  • time less then 1 year or over 5 years after transplantation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with fatigue and cognitive dysfunction

    Patients that are one to five years after allogeneic stem cell transplantation and have signs of fatigue and cognitive dysfunction measured by international standarts.

  • Patients without fatigue and cognitive dysfunction

    Patients that are one to five years after allogeneic stem cell transplantation and have no detectable signs of fatigue and cognitive dysfunction measured by international standarts.

06

What researchers measure

Primary outcomes

  1. Results of cognitive tests

    Measured by CANTAB and Geras panels

    Time frame: 2024-2027

  2. Potential biomarkers for fatigue and cognitive dysfunction

    Measured in blood and csf by using mass spectrometry-based proteomics approaches and Olink technology by selecting different panels of proteins based on data available in the literature.

    Time frame: 2024-2027

  3. PET results

    The primary analysis will focus on the frontal cortex.

    Time frame: 2024-2027

Secondary outcomes

  1. Global analyses of the neural connections

    Global analyses of the neural connections have recently been suggested as potentially important biomarkers of neurocognitive dysfunction after aHSCT

    Time frame: 2024-2027

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2026, 24 months after the start.

Of 156 non-industry observational studies under Fatigue, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 45. This study's planned 24 months is close to that.

Counting every sponsor, half of 166 studies reached it within 24 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2024
First posted
Apr 12, 2024
StartActual
Feb 22, 2024
Primary completionEst.
Feb 22, 2026
CompletionEst.
Feb 22, 2027
Last update
Apr 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06363396
Responsible party
Ksenia Boriskina (MD, Karolinska Institutet) — Principal investigator
First posted
Apr 12, 2024
Start date
Feb 22, 2024
Primary completion
Feb 22, 2026 (estimated)
Completion
Feb 22, 2027 (estimated)
Last update
Apr 12, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion